Braidwell’s DexCom DXCM Stock Holding History

Braidwell’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-441,086	Closed	-$29.6M	–	80
2024 Q3	$29.6M	Buy	+441,086	New	+$36.2M	0.84%	44

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Braidwell's DXCM Position: Q4 2024 in Review

Braidwell sold out of DexCom (DXCM) in Q4 2024, closing a stake of 441,086 shares — an estimated $29.6M sold.

Braidwell first reported a position in DXCM in Q3 2024 and held it in 1 quarter. The position peaked at $29.6M in Q3 2024. 952 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

Braidwell reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
Braidwell sold 441,086 DexCom shares in Q4 2024, an estimated $29.6M.
Braidwell first reported a position in DexCom in Q3 2024 and held it in 1 quarter.
Braidwell's DexCom position peaked at $29.6M in Q3 2024.
952 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.